Janus Henderson Group PLC reduced its stake in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 57.7% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 4,246,045 shares of the company's stock after selling 5,800,981 shares during the quarter. Janus Henderson Group PLC owned approximately 0.24% of AbbVie worth $754,554,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ABBV. Humankind Investments LLC raised its stake in shares of AbbVie by 22.1% during the 4th quarter. Humankind Investments LLC now owns 18,323 shares of the company's stock worth $3,256,000 after purchasing an additional 3,316 shares in the last quarter. Guardian Wealth Advisors LLC NC grew its stake in shares of AbbVie by 9.8% in the 4th quarter. Guardian Wealth Advisors LLC NC now owns 8,561 shares of the company's stock valued at $1,521,000 after buying an additional 761 shares in the last quarter. Forest Hill Capital LLC increased its holdings in AbbVie by 16.7% in the fourth quarter. Forest Hill Capital LLC now owns 4,200 shares of the company's stock worth $746,000 after buying an additional 600 shares during the last quarter. Elefante Mark B bought a new position in AbbVie during the fourth quarter valued at approximately $638,000. Finally, Ensign Peak Advisors Inc lifted its stake in AbbVie by 1.5% in the fourth quarter. Ensign Peak Advisors Inc now owns 2,059,389 shares of the company's stock valued at $365,953,000 after acquiring an additional 29,697 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.
AbbVie Trading Down 0.7 %
Shares of ABBV stock opened at $184.30 on Friday. The firm has a fifty day moving average of $194.23 and a 200-day moving average of $187.23. The stock has a market cap of $326.02 billion, a price-to-earnings ratio of 76.79, a P/E/G ratio of 1.62 and a beta of 0.56. AbbVie Inc. has a 52-week low of $153.58 and a 52-week high of $218.66. The company has a debt-to-equity ratio of 17.94, a quick ratio of 0.55 and a current ratio of 0.66.
AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.40 by $0.06. AbbVie had a net margin of 7.59% and a return on equity of 296.28%. The firm had revenue of $13.34 billion during the quarter, compared to analyst estimates of $12.91 billion. During the same quarter in the prior year, the business posted $2.31 earnings per share. The company's quarterly revenue was up 8.4% compared to the same quarter last year. On average, equities research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.
AbbVie Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be paid a $1.64 dividend. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.56%. AbbVie's dividend payout ratio is presently 279.15%.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on the stock. BNP Paribas upgraded shares of AbbVie to a "hold" rating in a report on Thursday. Citigroup boosted their price target on AbbVie from $205.00 to $215.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Raymond James reissued an "outperform" rating and set a $220.00 price objective (up previously from $218.00) on shares of AbbVie in a report on Monday, February 3rd. BMO Capital Markets boosted their target price on AbbVie from $208.00 to $215.00 and gave the stock an "outperform" rating in a report on Monday, February 3rd. Finally, Erste Group Bank upgraded AbbVie to a "strong-buy" rating in a report on Monday, March 17th. Seven analysts have rated the stock with a hold rating, eighteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $211.41.
Check Out Our Latest Stock Analysis on ABBV
Insider Transactions at AbbVie
In related news, EVP Jeffrey Ryan Stewart sold 58,832 shares of the stock in a transaction that occurred on Monday, March 31st. The stock was sold at an average price of $210.08, for a total transaction of $12,359,426.56. Following the sale, the executive vice president now directly owns 53,234 shares in the company, valued at $11,183,398.72. This represents a 52.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Perry C. Siatis sold 5,778 shares of AbbVie stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $197.90, for a total value of $1,143,466.20. Following the completion of the transaction, the executive vice president now owns 22,381 shares of the company's stock, valued at approximately $4,429,199.90. The trade was a 20.52 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 113,471 shares of company stock valued at $23,426,451. 0.08% of the stock is owned by insiders.
About AbbVie
(
Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
